These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 11452675)

  • 1. The health economic impact of antidepressant usage from a payer's perspective: a multinational study.
    Casciano J; Doyle J; Arikian S; Casciano R
    Int J Clin Pract; 2001 Jun; 55(5):292-9. PubMed ID: 11452675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
    Demyttenaere K; Hemels ME; Hudry J; Annemans L
    Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
    Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
    Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care.
    Sørensen J; Stage KB; Damsbo N; Le Lay A; Hemels ME
    Nord J Psychiatry; 2007; 61(2):100-8. PubMed ID: 17454724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial.
    Leelahanaj T
    J Med Assoc Thai; 2012 May; 95 Suppl 5():S29-37. PubMed ID: 22934442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.
    Akkaya C; Sivrioglu EY; Akgoz S; Eker SS; Kirli S
    Hum Psychopharmacol; 2006 Jul; 21(5):337-45. PubMed ID: 16856215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desvenlafaxine: another "me too" drug?
    Sopko MA; Ehret MJ; Grgas M
    Ann Pharmacother; 2008 Oct; 42(10):1439-46. PubMed ID: 18698015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost of depression in Europe.
    Sobocki P; Jönsson B; Angst J; Rehnberg C
    J Ment Health Policy Econ; 2006 Jun; 9(2):87-98. PubMed ID: 17007486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacoeconomic evaluation of major depressive disorder (Italy).
    Casciano J; Arikian S; Tarride JE; Doyle JJ; Casciano R
    Epidemiol Psichiatr Soc; 1999; 8(3):220-31. PubMed ID: 10638040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of unrecognized bipolar disorders among patients treated for depression with antidepressants in the fee-for-services California Medicaid (Medi-Cal) program: a 6-year retrospective analysis.
    McCombs JS; Ahn J; Tencer T; Shi L
    J Affect Disord; 2007 Jan; 97(1-3):171-9. PubMed ID: 16860396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder.
    Ye W; Zhao Y; Robinson RL; Swindle RW
    BMC Psychiatry; 2011 Jan; 11():19. PubMed ID: 21281479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder.
    van Baardewijk M; Vis PM; Einarson TR
    Curr Med Res Opin; 2005 Aug; 21(8):1271-9. PubMed ID: 16083537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan.
    Sado M; Knapp M; Yamauchi K; Fujisawa D; So M; Nakagawa A; Kikuchi T; Ono Y
    Aust N Z J Psychiatry; 2009 Jun; 43(6):539-47. PubMed ID: 19440886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression.
    Trivedi MH; Lin EH; Katon WJ
    CNS Spectr; 2007 Aug; 12(8 Suppl 13):1-27. PubMed ID: 17986951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder.
    Simon JS; Aguiar LM; Kunz NR; Lei D
    J Psychiatr Res; 2004; 38(3):249-57. PubMed ID: 15003430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project.
    Trivedi MH; Rush AJ; Crismon ML; Kashner TM; Toprac MG; Carmody TJ; Key T; Biggs MM; Shores-Wilson K; Witte B; Suppes T; Miller AL; Altshuler KZ; Shon SP
    Arch Gen Psychiatry; 2004 Jul; 61(7):669-80. PubMed ID: 15237079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic impact of non-persistence to antidepressant therapy in the Quebec community-dwelling elderly population.
    Tournier M; Moride Y; Crott R; du Fort GG; Ducruet T
    J Affect Disord; 2009 May; 115(1-2):160-6. PubMed ID: 18694602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of usual general practitioner care with or without antidepressant medication for patients with minor or mild-major depression.
    Bosmans JE; Hermens ML; de Bruijne MC; van Hout HP; Terluin B; Bouter LM; Stalman WA; van Tulder MW
    J Affect Disord; 2008 Nov; 111(1):106-12. PubMed ID: 18342952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.